viewQ BioMed Inc.

Q BioMed’s partner Mannin Research developing treatment for deadly coronavirus

It is developing a new class of drugs that may boost survival rates by reducing endothelial cell dysfunction

Q BioMed Inc. - Q BioMed’s partner Mannin Research developing treatment for deadly coronavirus
At least 427 people have died with more than 20,000 confirmed cases around the world, most of them in China

Q BioMed Inc (OTCMKTS:QBIO) announced Tuesday that its research and technology partner, Mannin Research Inc, is developing new therapeutics to treat a variety of vascular diseases, including the strain of the deadly coronavirus from Wuhan in China. 

Mannin, a research-stage biotechnology company based in Toronto, has partnered with Q BioMed since 2015. 

In a statement, Q BioMed said Mannin is developing a new class of drugs to treat various vascular diseases. Its lead research platform targets the activation of the Angiopoietin-Tie2 signaling pathway. In a nutshell, Angiopoietin-1 promotes sprouting and survival of endothelial cells through the activation of different signaling pathways. 

READ: Q BioMed expects to start sales of its cancer pain drug early in first quarter

The company said that while Mannin is not generating a vaccine against infectious diseases, it is developing new therapeutics that may boost survival rates by reducing endothelial dysfunction (where the inner lining of the small arteries fails to perform) by enhancing host-directed therapeutic responses.

"We are working closely with our technology research partner Mannin to develop a potential adjunct treatment for various infectious diseases like the coronavirus,” said Q BioMed CEO Denis Corin.

“These types of outbreaks are not uncommon. H1N1, SARS, Ebola, pneumonia, influenza and others all can cause vascular leakage and respiratory distress in patients, which can be fatal in the most severe cases," he added.

According to BBC, at least 427 people have died after being infected with the coronavirus and there are more than 20,000 confirmed cases around the world, most of them in China.

"Mannin's research team and collaborations in Canada, Germany, and the United States, are working to develop novel drugs to treat vascular leakage and endothelial dysfunction, which is common in severe cases of influenza, as well as in the current coronavirus outbreak,” said Mannin Research CEO George N. Nikopoulos.

Last September, Mannin received a $7.5 million grant from the German state of Saxony to fund the development of its novel therapeutics, including drugs and biologics that reduce endothelial dysfunction and loss of endothelial barrier integrity, which are central to the pathophysiology of viral and bacterial infections resulting in acute and severe lung injury.

Recently, Mannin submitted a funding application to the Small Business Technology Transfer Grant run by the US National Institutes of Health to investigate specific applications of its therapeutic platform.

Q BioMed shares added 0.90% in New York to $2.25.

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive 

Quick facts: Q BioMed Inc.

Price: 1.7 USD

Market: OTCQB
Market Cap: $38.6 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...



Q BioMed advancing its liver cancer treatment through the pipeline

Q BioMed Inc (OTCMKTS:QBIO) CEO Denis Corin tells Proactive the biotech will advance Uttroside-B in its portfolio and move it quickly towards monetization. Corin says the efficacy of Uttroside-B, a potent saponin, was demonstrated in a preclinical study published in the November 2016 issue of...

2 weeks, 3 days ago

2 min read